Is there a room for Quicksilver Resources Inc (NYSE:KWK) to move up, Celsion Corporation (NASDAQ:CLSN)

Posted by Nathan Alexander May 15, 2013 0 Comment 1374 views


Miami, FL 05/15/2013 (GDPInsider) – Quicksilver Resources Inc (NYSE:KWK): Tuesday’s trading session saw Quicksilver Resources Inc (NYSE:KWK) shares headed 1.70% upward. The opening price of $2.36 touched an intraday high of $2.43 per share before setting to $2.39. The average volume of 3.31 million shares was measured over a period of 30 days.

Quicksilver Resources has announced that it is now withdrawing its Initial Public Offering due to the weakening of natural gas liquids’ prices. Another reason that has been cited by the company is that it had sold 25% of its Barnett Shale holdings to the Tokyo Gas Co. The IPO plans had been unveiled last year.  KWK reported losses for the fifth consecutive quarter and the IPO had been valued at $250 million.

Quicksilver Resources Inc (NYSE:KWK) is an independent oil and gas company. It is primarily engaged in the acquisition of, exploring, developing and production of onshore oil and gas in the North American region. It focuses on unconventional reservoirs and operates in the geographic segments of U.S. and Canada.

Is KWK a solid investment at these levels? Get valuable updates and exclusive insights here.

Celsion Corporation (NASDAQ:CLSN): Tuesday’s trading session saw Celsion Corporation (NASDAQ:CLSN) shares headed 0.18% upward. The opening price of $0.97 touched an intraday high of $0.97 per share before setting to $0.959. The average volume of 1.79 million shares was measured over a period of 30 days.

Celsion Corporation is an oncology drug-development company. It focuses on the development of treatments that are used in patients who suffer from different forms of cancer. As of 31 December 2011, ThermoDox, Celsion Corporation (NASDAQ:CLSN)’s product is under evaluation in a Phase-III clinical trial for the treatment of primary liver cancer (the HEAT study) It is also undergoing a Phase-II clinical trial for recurrent chest wall breast cancer and Phase-II clinical trial for the treatment of colorectal liver metastasis (CRLM). ThermoDox is essentially a liposomal encapsulation of doxorubicin. This is an approved and regularly-used oncology drug that is used in the treatment of different forms of cancer.

How Should Investors Trade CLSN Now? Get the latest trends and data here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Nathan Alexander

Nathan Alexander holds bachelor’s degrees in Journalism and European Studies from Boston University. Nathan reports round up the day’s business and financial market news and include keynote interviews with major business players and updates on Asian, European and US stock markets. He has interviewed heads of leading European banking institutions such as European Central Bank President Jean-Claude Trichet and HSBC Chairman Stephen Green, and CEOs from the business world including Microsoft founder Bill Gates, Virgin Chairman Sir Richard Branson and former Porsche President and CEO Dr Wendelin Wiedeking.

View all post by Nathan Alexander Visit author's website

Write Your Comment